Stealth BioTherapeutics
US-based Stealth BioTherapeutics develops therapies for genetic mitochondrial and age-related diseases.
US-based Stealth BioTherapeutics develops therapies for genetic mitochondrial and age-related diseases.
Stealth BioTherapeutics, founded in Newton, United States, is dedicated to developing therapies for mitochondrial dysfunction associated with genetic mitochondrial diseases and common age-related conditions. The company's core mission is to innovate and deliver new treatment solutions to improve the quality of life for patients suffering from these disorders, which currently lack FDA-approved treatments. Their market focus primarily includes the medical sectors in the United States and the Cayman Islands.
Notable affiliated individuals and investors include experts in mitochondrial biology and seasoned pharmaceutical executives. Stealth BioTherapeutics has achieved significant milestones in advancing its therapeutic candidates through clinical trials, demonstrating potential efficacy in treating mitochondrial dysfunction. The overall impact of the company lies in its commitment to addressing unmet medical needs, thereby contributing to the advancement of mitochondrial medicine and improving patient outcomes.
Companies similar to Stealth BioTherapeutics include Stealth Therapeutics, Secretome Therapeutics, Marlinspike Therapeutics and Santiste Medical.
Stealth BioTherapeutics was founded in 2007.
Stealth BioTherapeutics' headquarters is located in Needham, MA, US.
Stealth BioTherapeutics' most recent funding round was for $8.5M (USD) in April 2022.
As of Apr 11, 2022, Stealth BioTherapeutics has raised a total of $191.4M (USD).
Stealth BioTherapeutics has 52 employees as of Feb 5, 2024.
Marlinspike Therapeutics
